Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Current Deferred Revenue (2017 - 2023)

Historic Current Deferred Revenue for Denali Therapeutics (DNLI) over the last 7 years, with Q2 2023 value amounting to $1.3 million.

  • Denali Therapeutics' Current Deferred Revenue changed N/A to $1.3 million in Q2 2023 from the same period last year, while for Jun 2023 it was $1.3 million, marking a year-over-year change of. This contributed to the annual value of $290.1 million for FY2022, which is 93905.79% up from last year.
  • As of Q2 2023, Denali Therapeutics' Current Deferred Revenue stood at $1.3 million.
  • Over the past 5 years, Denali Therapeutics' Current Deferred Revenue peaked at $290.4 million during Q1 2023, and registered a low of $23000.0 during Q3 2022.
  • Its 5-year average for Current Deferred Revenue is $51.2 million, with a median of $21.3 million in 2019.
  • The largest annual percentage gain for Denali Therapeutics' Current Deferred Revenue in the last 5 years was 93905.79% (2022), contrasted with its biggest fall of 9826.28% (2022).
  • Denali Therapeutics' Current Deferred Revenue (Quarter) stood at $18.7 million in 2019, then increased by 6.27% to $19.9 million in 2020, then skyrocketed by 40.18% to $27.9 million in 2021, then skyrocketed by 939.06% to $290.1 million in 2022, then crashed by 99.55% to $1.3 million in 2023.
  • Its last three reported values are $1.3 million in Q2 2023, $290.4 million for Q1 2023, and $290.1 million during Q4 2022.